Bank of America’s BioCryst Pharmaceuticals BCRX Stock Holding History

Bank of America’s Portfolio BCRX Stock Details BCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-22,500	Closed	-$188K	–	7709
2023 Q1	$188K	Buy	+22,500	New	+$217K	﹤0.01%	5954
2022 Q2	–	Sell	-30,000	Closed	-$488K	–	8005
2022 Q1	$488K	Buy	+30,000	New	+$481K	﹤0.01%	5851
2021 Q4	–	Sell	-22,000	Closed	-$316K	–	8213
2021 Q3	$316K	Sell	22,000 -28,000	-56%	-$442K	﹤0.01%	5976
2021 Q2	$790K	Buy	+50,000	New	+$679K	﹤0.01%	5088
2015 Q3	–	Sell	-104,800	Closed	-$1.56M	–	7204
2015 Q2	$1.56M	Buy	+104,800	New	+$1.19M	﹤0.01%	3711

Other funds holding BCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VPC

Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return

Bank of America's BCRX Position: Q1 2026 in Review

Bank of America increased its BioCryst Pharmaceuticals (BCRX) stake by 232% in Q1 2026, buying an estimated $27.6M and bringing the position to 5,091,765 shares worth $48.5M. The position accounts for ﹤0.01% of the portfolio, ranked #1615.

Bank of America first reported a position in BCRX in Q2 2013 and has held it in 52 quarters since. 301 funds tracked by Wall St. Rank hold BCRX as of Q1 2026.

Bank of America held 5,091,765 shares of BioCryst Pharmaceuticals worth $48.5M as of Q1 2026.
Bank of America bought 3,556,208 BioCryst Pharmaceuticals shares in Q1 2026, an estimated $27.6M.
BioCryst Pharmaceuticals made up ﹤0.01% of Bank of America's portfolio in Q1 2026, its #1615 holding.
Bank of America first reported a position in BioCryst Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
301 funds tracked by Wall St. Rank held BioCryst Pharmaceuticals as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.